Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme/Schering AG To Initiate Campath Phase III Trial For MS

This article was originally published in The Pink Sheet Daily

Executive Summary

Firms agree with FDA on Phase III plan despite suspension of Phase II program following three cases of severe idiopathic thrombocytopenic purpura.
Advertisement

Related Content

Genzyme’s Campath MS Safety Profile Expected From FDA By July; Phase III Set For Second Half
Genzyme’s Campath MS Safety Profile Expected From FDA By July; Phase III Set For Second Half
FDA Alert Warns Of Adverse Events With Genzyme/Schering AG's Campath
FDA Alert Warns Of Adverse Events With Genzyme/Schering AG's Campath
Campath Could Be Approved For Multiple Sclerosis By 2009, Genzyme Says
Campath Could Be Approved For Multiple Sclerosis By 2009, Genzyme Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS062896

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel